New India Assurance Jumps 20% on Premium Growth, Tax Concerns Linger

INSURANCE
Whalesbook Logo
AuthorRiya Kapoor|Published at:
New India Assurance Jumps 20% on Premium Growth, Tax Concerns Linger
Overview

New India Assurance shares closed up 19.78% at ₹155.90 on Thursday, driven by 10.9% year-on-year premium growth for FY26 and a slight market share increase to 12.74%. The company's price-to-book ratio below 1 attracted investor interest. However, recent quarterly results revealed a significant profit decline, and a substantial tax assessment order raises concerns.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Premium Growth Fuels Share Surge

New India Assurance shares surged 19.78% to ₹155.90 on Thursday, April 9, 2026, on the BSE. This jump followed the company's announcement of a 10.9% year-on-year increase in premium collection for fiscal year 2025-26. This growth surpassed the broader non-life insurance industry's 9.3% expansion. The insurer also slightly boosted its market share to 12.74% from 12.56% a year prior. Trading volume reached 65.65 lakh shares, showing strong investor interest.

Valuation Metrics and Analyst Outlook

The company's valuation metrics present a mixed view. Its price-to-book (P/B) ratio is around 0.91-0.92, trading below book value. The trailing twelve months (TTM) price-to-earnings (P/E) ratio is 17.2x-18.31x, lower than competitors like ICICI Lombard (around 31.5x). However, compared to the Asian insurance industry's average P/E of 11.3x, New India Assurance seems pricier. The Indian non-life insurance sector is expected to grow gross written premiums by 13% in FY26, with a medium-term CAGR of 8-11%. New India Assurance's 10.87% growth fits this trend. Three analysts rate the stock a 'Buy' with a median 12-month price target of ₹165, and some targets reaching ₹193.33. The company confirmed regulatory adherence by filing its quarterly compliance certificate.

Profit Drop and Tax Order Cloud Gains

Despite the rally, significant concerns exist. The company's market share of 12.74% is still modest compared to market leaders. Recent performance figures are worrying; net profit fell 39.0% year-on-year in the second quarter of fiscal year 2026, despite revenue growth. The company also faces a substantial tax impact of ₹1,893.7 crore from an Income Tax Department assessment order for assessment year 2023-24. These factors, alongside sector issues like medical inflation, could slow future growth. While some analysts recommend 'Buy' with higher targets, others suggest 'Hold' or 'Sell' with targets as low as ₹100.

Navigating Challenges Ahead

Looking ahead, analysts maintain a generally positive outlook with a consensus 'Buy' rating. However, recent profit dips and tax liabilities temper this view. Future earnings per share are forecast to grow around 10% annually, with revenue growth projected at 7.6%. Investors will watch how the company handles the Q2 FY26 profit decline and the tax assessment. The average analyst price target of ₹193.33 suggests potential upside, but consistent bottom-line improvement is key for sustained investor confidence.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.